[go: up one dir, main page]

ZA200906899B - Process for preparation of erlotinib and its pharmaceutically acceptable salts - Google Patents

Process for preparation of erlotinib and its pharmaceutically acceptable salts

Info

Publication number
ZA200906899B
ZA200906899B ZA200906899A ZA200906899A ZA200906899B ZA 200906899 B ZA200906899 B ZA 200906899B ZA 200906899 A ZA200906899 A ZA 200906899A ZA 200906899 A ZA200906899 A ZA 200906899A ZA 200906899 B ZA200906899 B ZA 200906899B
Authority
ZA
South Africa
Prior art keywords
erlotinib
preparation
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
ZA200906899A
Other languages
English (en)
Inventor
Dharmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of ZA200906899B publication Critical patent/ZA200906899B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ZA200906899A 2007-04-04 2009-01-01 Process for preparation of erlotinib and its pharmaceutically acceptable salts ZA200906899B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN681MU2007 2007-04-04

Publications (1)

Publication Number Publication Date
ZA200906899B true ZA200906899B (en) 2010-05-26

Family

ID=39580101

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200906899A ZA200906899B (en) 2007-04-04 2009-01-01 Process for preparation of erlotinib and its pharmaceutically acceptable salts

Country Status (9)

Country Link
US (2) US8642758B2 (fr)
EP (1) EP2139868B1 (fr)
JP (2) JP5524041B2 (fr)
KR (2) KR101441930B1 (fr)
AU (1) AU2008235274B2 (fr)
CA (1) CA2682013C (fr)
NZ (1) NZ579997A (fr)
WO (1) WO2008122776A2 (fr)
ZA (1) ZA200906899B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2139868B1 (fr) 2007-04-04 2015-07-29 Cipla Limited Procédé de préparation de l'erlotinib et de ses sels pharmaceutiquement acceptables
WO2009007984A2 (fr) * 2007-07-11 2009-01-15 Hetero Drugs Limited Procédé amélioré pour l'hydrochlorate d'erlotinibe
WO2010040212A1 (fr) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Procédés de préparation du chlorhydrate d'erlotinib
CN101735156B (zh) * 2008-11-20 2012-07-04 上海医药工业研究院 厄罗替尼盐酸盐的多晶型l、其制备方法及其应用
EP2411373B1 (fr) 2009-03-26 2015-10-21 Ranbaxy Laboratories Limited Procede de preparation d'erlotinib ou de ses sels pharmaceutiquement acceptables
CN101863844B (zh) * 2009-04-16 2012-10-03 欧美嘉股份有限公司 6,7-取代基-4-苯胺类喹唑啉的合成方法
CN102746242A (zh) * 2009-04-16 2012-10-24 欧美嘉股份有限公司 6,7-取代基-4-苯胺类喹唑啉的合成方法
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068403A2 (fr) * 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Nouveaux sels de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine
EP2348020A1 (fr) * 2009-12-23 2011-07-27 Esteve Química, S.A. Procédé de préparation d'erlotinib
WO2011147102A1 (fr) * 2010-05-28 2011-12-01 翔真生物科技股份有限公司 Procédé de synthèse d'une 4-aniline-quinazoline substituée aux positions 6 et 7
JP5948597B2 (ja) * 2010-07-23 2016-07-06 ジェネリクス・［ユーケー］・リミテッド 純粋なエルロチニブ
CN101891691A (zh) * 2010-07-30 2010-11-24 天津市炜杰科技有限公司 一种盐酸埃罗替尼的制备方法
KR20130136465A (ko) * 2010-10-22 2013-12-12 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 유기 전계발광 소자
CN102863395A (zh) * 2011-07-04 2013-01-09 北京六盛合医药科技有限公司 一种厄洛替尼的合成新方法
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
CN102827087B (zh) * 2012-06-18 2015-03-25 中国科学院成都生物研究所 一种厄洛替尼的合成方法
WO2014037961A1 (fr) 2012-09-04 2014-03-13 Shilpa Medicare Limited Procédé de préparation de la forme cristalline de chlorhydrate d'erlotinib
CN103772298A (zh) * 2012-10-25 2014-05-07 鲁南制药集团股份有限公司 一种盐酸厄罗替尼多晶型物及其制备方法
WO2014118737A1 (fr) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Sels d'erlotinib
CN103275020A (zh) * 2013-05-06 2013-09-04 苏州立新制药有限公司 厄洛替尼的制备方法
CN103709110B (zh) * 2013-12-13 2016-05-04 浙江普洛康裕制药有限公司 一种盐酸厄洛替尼关键中间体的制备方法
CN103980207B (zh) * 2014-04-04 2016-03-09 亿腾药业（泰州）有限公司 一种盐酸厄洛替尼b型晶的合成方法
CN104250230A (zh) * 2014-09-05 2014-12-31 亿腾药业（泰州）有限公司 厄洛替尼柠檬酸盐与其晶型以及它们的制备方法
CN104725327B (zh) * 2015-03-03 2017-08-25 山东大学 一种盐酸厄洛替尼的环保制备方法
CN107655983B (zh) * 2016-07-25 2021-08-27 重庆华邦胜凯制药有限公司 盐酸厄洛替尼的关键起始原料三乙炔苯胺中潜在基因毒性杂质的分离与测定方法
CN106928069B (zh) * 2017-03-21 2019-03-19 上海玉函化工有限公司 一种4,5-二(2-甲氧基乙氧基)-2-硝基苯甲酸乙酯的制备方法
CN108358798A (zh) * 2018-02-12 2018-08-03 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成厄洛替尼中间体的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK159079A (da) * 1978-05-18 1979-11-19 Pfizer Fremgangsmaade til fremstilling af derivater af 4-amino-2-piperidinoquinazolin eller syreadditionssalte deraf
CA2216796C (fr) * 1995-03-30 2003-09-02 Pfizer Inc. Derives de quinazoline
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CN1298396A (zh) * 1998-04-29 2001-06-06 Osi药物公司 N－(乙炔苯氨基)－6,7－双(2－甲氧基乙氧基)－4－喹唑啉胺甲磺酸盐无水物和一水合物
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP2139868B1 (fr) 2007-04-04 2015-07-29 Cipla Limited Procédé de préparation de l'erlotinib et de ses sels pharmaceutiquement acceptables

Also Published As

Publication number Publication date
AU2008235274A1 (en) 2008-10-16
NZ579997A (en) 2012-08-31
JP2010523535A (ja) 2010-07-15
EP2139868B1 (fr) 2015-07-29
US20140194624A1 (en) 2014-07-10
WO2008122776A2 (fr) 2008-10-16
EP2139868A2 (fr) 2010-01-06
US20100094004A1 (en) 2010-04-15
US8642758B2 (en) 2014-02-04
KR20100017095A (ko) 2010-02-16
KR20140069232A (ko) 2014-06-09
KR101441930B1 (ko) 2014-09-19
AU2008235274B2 (en) 2013-04-18
WO2008122776A3 (fr) 2009-03-26
JP5524041B2 (ja) 2014-06-18
JP2014129362A (ja) 2014-07-10
CA2682013C (fr) 2015-06-30
CA2682013A1 (fr) 2008-10-16

Similar Documents

Publication Publication Date Title
ZA200906899B (en) Process for preparation of erlotinib and its pharmaceutically acceptable salts
IL206500A0 (en) Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
EP2086945A4 (fr) Nouveau procédé de préparation de statines et leurs sels pharmaceutiquement acceptables
EP2499147A4 (fr) Procedes perfectionnes et nouveaux de preparation de prasugrel, de ses intermediaires et de sels de qualite pharmaceutique
PL2362875T3 (pl) Proces do wytwarzania alfa-tokotrienolu i pochodnych
SI1981863T1 (sl) Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
IL206544A0 (en) Methods of preparing quinazolinone derivatives
IL198847A0 (en) New process for the preparation of 2-imino-thiazolidin-4-one derivatives
IL206394A (en) Derivatives of 2-Benzylpyridine Filtration as Met Kinase Inhibitors, Process for their Preparation, Medication and Use
IL193236A0 (en) Novel pyrone-indole derivatives and process for their preparation
PT2170844T (pt) Novos polimorfos de cloridrato de erlotinib e método de preparação
PL2400954T3 (pl) Sposób wytwarzania stałych, doustnych postaci solifenacyny i jej farmaceutycznie dopuszczalnych soli
EP2069329A4 (fr) Procédé pour la préparation de dérivés de benzimidazole, et de leurs sels
EP1968943A4 (fr) Procede ameliore de preparation de montelukast et de ses sels pharmaceutiquement acceptables
ZA200902575B (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
IL205082A0 (en) Process for the preparation of tetranorlabdane derivatives
EP2069307A4 (fr) Procédé pour la préparation de montelukast et de ses sels
PL2291374T3 (pl) Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej
PL2170920T3 (pl) Stabilne sole s-adenozylometioniny i sposób ich wytwarzania
GB0606234D0 (en) Pharmaceutically acceptable salts and polymorphic forms
EP2121729A4 (fr) Sels pharmaceutiquement acceptables de la thymodépressine et leurs procédés de fabrication
IL219872A (en) Quinazoline derivatives, their uses, their preparation, and their medications
ZA201000802B (en) Process for the preparation of alfuzosin hydrochloride
PT2419407E (pt) Processo melhorado para a preparação de fluvastatina e dos seus sais
ZA201000159B (en) Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof